From the payers' own documents
Coverage policy, by payer
Prior-authorization criteria, step therapy, quantity limits, appeal routes and dated formulary changes — drawn from the payers' own published documents wherever they exist, with a confidence grade on everything else.
Aetna (CVS Health)
Insurer (Caremark-administered)
- Foundayo™ (orforglipron) Preferred
- Wegovy® (semaglutide injection) Preferred
- Wegovy® tablets (oral semaglutide) Preferred
- Zepbound® (tirzepatide) Preferred
Criteria are essentially identical to the Caremark template (same BMI wording, 6-month program requirement, 5% reauth gate, same quantity limits). The difference is formulary architecture: standard Aetna commercial formularies made Zepbound exception-only after July 2025 with a step through Wegovy, while FE-compatible plans kept it PA-covered. Many Aetna plans exclude weight-loss drugs entirely (CPB 0039).
Blue Cross Blue Shield Federal Employee Program (FEP)
National uniform plan (published criteria)
- Foundayo™ (orforglipron) Unknown
- Saxenda® (liraglutide) Covered
- Wegovy® (semaglutide injection) Covered
- Wegovy® tablets (oral semaglutide) Covered
- Zepbound® (tirzepatide) Exception only
Restructured the class for 2026 citing GLP-1 cost growth: Zepbound moved to the Standard-option excluded list (obtainable only via formulary exception meeting policy 5.99.031, which adds a new two-oral-agents step plus preferred-product trial), while Wegovy and Saxenda held at Tier 3 with PA. Focus covers no BRAND anti-obesity drug -- but it is not the blank this file used to call it: generic liraglutide for weight management and orlistat sit on the Focus list at Tier 1 with prior approval, which is the cheapest tier FEP has. One uniform national plan with genuinely published criteria — the most transparent payer in this corpus.
CVS Caremark
PBM standard commercial template
- Foundayo™ (orforglipron) Covered
- Saxenda® (liraglutide) Covered
- Wegovy® (semaglutide injection) Preferred
- Wegovy® tablets (oral semaglutide) Covered
- Zepbound® (tirzepatide) Preferred
Largest US PBM. Removed Zepbound from standard commercial template formularies July 1, 2025 (Wegovy preferred); returns Zepbound as an additional preferred option October 1, 2026. CVS publishes no member cost-share figure for that return — what a member pays is set by their plan. Template criteria — plan sponsors customize, and many employer plans exclude weight-loss drugs entirely.
Elevance Health / Anthem (CarelonRx)
Insurer + PBM
- Foundayo™ (orforglipron) Preferred
- Saxenda® (liraglutide) Varies
- Wegovy® (semaglutide injection) Preferred
- Wegovy® tablets (oral semaglutide) Preferred
- Zepbound® (tirzepatide) Preferred
The stable one: kept Wegovy AND Zepbound dual-preferred (Tier 2, PA/QL) through the 2025 upheavals, and added Foundayo fastest of the majors (May 15, 2026). Coverage still contingent on the employer including a weight-loss benefit. No single national criteria PDF — criteria served per-drug via the Anthem Drug List Search.
Express Scripts (Evernorth / Cigna)
PBM standard commercial template (National Preferred Formulary)
- Foundayo™ (orforglipron) Preferred
- Saxenda® (liraglutide) Excluded
- Wegovy® (semaglutide injection) Preferred
- Wegovy® tablets (oral semaglutide) Preferred
- Zepbound® (tirzepatide) Preferred
Kept both Wegovy and Zepbound single-dose pens preferred through the 2025 upheaval. 2026 NPF: Zepbound pens, Wegovy (pens, HD, tablets), and Foundayo all preferred — but Zepbound KwikPens and vials are excluded (device-level steering), and Saxenda is excluded in favour of generic liraglutide. PA criteria run through the Cigna National Formulary policies, which since June 2026 are published one per drug rather than as a single combined document. The 2027 NPF exclusions list, published 08/01/2026, carries this class forward with no change: the same two Zepbound presentations excluded, the same six agents named as preferred alternatives, and Saxenda still excluded in favour of generic liraglutide — so the device-level steering survives into the 2027 plan year.
Humana
Medicare-focused (no employer commercial book)
- Foundayo™ (orforglipron) Excluded
- Saxenda® (liraglutide) Excluded
- Wegovy® (semaglutide injection) Excluded
- Zepbound® (tirzepatide) Excluded
Humana exited employer-group commercial medical (completed ~2024) — treat 'Humana commercial' as N/A; several consumer sites erroneously describe active plans. Its Part D formularies exclude weight-loss GLP-1s (statute), covering CV/MASH/OSA indications with PA on some formularies. Unusual dual role: Humana is CMS's central processor for the Medicare GLP-1 Bridge (BIN 028918, PCN MEDDGLP1BR), adjudicating $50 Bridge claims for all Medicare beneficiaries nationwide.
Kaiser Permanente
Integrated system (regional formularies)
- Foundayo™ (orforglipron) Unknown
- Saxenda® (liraglutide) Varies
- Wegovy® (semaglutide injection) Varies
- Wegovy® tablets (oral semaglutide) Unknown
- Zepbound® (tirzepatide) Varies
Regional variance is the defining feature, and Kaiser runs the strictest step therapy of any major payer: the NW region requires failing TWO oral weight-loss agents AND a 6-month semaglutide trial before Zepbound. California base commercial plans removed Wegovy for BMI < 40 effective 1/1/2025 (employer opt-in otherwise). Formulary exceptions are functionally in-house bariatric-medicine reviews.
Medicaid (state-by-state)
State programs + BALANCE model
- Wegovy® (semaglutide injection) Varies
- Zepbound® (tirzepatide) Varies
Coverage of GLP-1s for obesity is state-by-state and shrinking: 13 states as of Jan 2026 (KFF count), 11 at the RX Index tracker's July 10, 2026 snapshot after Utah's pilot ended June 30 and MassHealth ended coverage July 3. Every count here is dated to the snapshot that produced it — neither source publishes a current national total, and the tracker says so explicitly. Rhode Island stops covering GLP-1s prescribed solely for weight loss on Oct 1, 2026 under its enacted FY2027 budget, taking the count to 10 — other medically accepted indications stay reachable there by prior authorization. Four states had already ELIMINATED coverage Jan 1, 2026 (CA, NH, PA, SC). The CMS BALANCE model lets states buy in at negotiated prices with rolling starts May 2026 - Jan 2027; its negotiated drug list is all formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo, for their diabetes indications as well as weight management. CMS says Medicaid coverage under the model depends on both manufacturer and state participation and guarantees coverage to no individual. CMS still published no participating-state list as of Oct 19, 2026 — its model page carries no participant count — and state agreements with CMS are due by Jan 1, 2027; applications closed July 31. Indiana said on Jul 30, 2026 that it would take part, which is the state's own announcement rather than a CMS list entry.
Medicare (Part D + GLP-1 Bridge)
Federal program
- Foundayo™ (orforglipron) Covered
- Ozempic® (semaglutide) Covered
- Saxenda® (liraglutide) Excluded
- Wegovy® (semaglutide injection) Covered
- Wegovy® tablets (oral semaglutide) Covered
- Zepbound® (tirzepatide) Covered
Weight-loss-only GLP-1 use remains statutorily EXCLUDED from Part D (2003 MMA). The temporary Medicare GLP-1 Bridge (July 1, 2026 - Dec 31, 2027) fills the gap at a flat $50/month for Foundayo, Wegovy (all forms), and Zepbound KwikPen — running entirely outside the Part D plan. Diabetes (Ozempic/Mounjaro) and secondary indications (Zepbound-OSA, Wegovy-CV) route through standard Part D with PA.
Optum Rx (UnitedHealthcare)
PBM standard commercial template (Premium Standard Formulary)
- Foundayo™ (orforglipron) Varies
- Saxenda® (liraglutide) Covered
- Wegovy® (semaglutide injection) Covered
- Wegovy® tablets (oral semaglutide) Varies
- Zepbound® (tirzepatide) Covered
Kept both Wegovy and Zepbound covered throughout 2025-2026 — no CVS-style exclusion — with PA + quantity limits throughout, though Zepbound is covered as the auto-injector only and the vials are excluded outright. Tier placement is a plan-level answer rather than a property of the formulary: booklets carrying the same 'Premium Standard Formulary' name and the same Jan 1 2026 effective date print these drugs at Tier 2 in one case and Tier 3 in another. Weight-loss coverage is an opt-in employer benefit. Foundayo joined the weight-loss PA policy on 9/1/2026 but has no published formulary tier and may be excluded at launch on some plans.
What these coverage words mean
Formulary vocabulary turns up on denial letters with no explanation. Here is what each term means on this site — including the two that describe a gap in our data rather than a decision by your plan.
- Preferred
- On the formulary at the plan's best tier for this class. Usually still needs prior authorization — preferred is not the same as automatic.
- Covered
- On the formulary, but not the plan's first choice for this class. Often a higher copay tier than a preferred drug.
- Non preferred
- On the formulary at a disadvantaged tier, or reachable only after trying a preferred drug first.
- Exception only
- Not routinely covered. Obtainable only through a formulary-exception request that meets the plan's published criteria.
- Excluded
- Not on the formulary at all. A benefit exclusion is a different fight from a PA denial and is appealed differently.
- Varies
- The payer's own documents differ by plan or line of business, so a single answer here would be wrong.
- Unknown
- Not yet verified against a primary document. Recorded as absent rather than guessed.
- N/A
- Not applicable to this payer.